HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium.

AbstractPURPOSE:
Studies of smoking and risk of non-Hodgkin lymphoma (NHL) have yielded inconsistent results, possibly due to subtype heterogeneity and/or genetic variation impacting the metabolism of tobacco-derived carcinogens, including substrates of the N-acetyltransferase enzymes NAT1 and NAT2.
METHODS:
We conducted a pooled analysis of 5,026 NHL cases and 4,630 controls from seven case-control studies in the international lymphoma epidemiology consortium to examine associations between smoking, variation in the N-acetyltransferase genes NAT1 and NAT2, and risk of NHL subtypes. Smoking data were harmonized across studies, and genetic variants in NAT1 and NAT2 were used to infer acetylation phenotype of the NAT1 and NAT2 enzymes, respectively. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for risk of NHL and subtypes were calculated using joint fixed effects unconditional logistic regression models.
RESULTS:
Current smoking was associated with a significant 30 % increased risk of follicular lymphoma (n = 1,176) but not NHL overall or other NHL subtypes. The association was similar among NAT2 slow (OR 1.36; 95 % CI 1.07-1.75) and intermediate/rapid (OR 1.27; 95 % CI 0.95-1.69) acetylators (p (interaction) = 0.82) and also did not differ by NAT1*10 allelotype. Neither NAT2 phenotype nor NAT1*10 allelotype was associated with risk of NHL overall or NHL subtypes.
CONCLUSION:
The current findings provide further evidence for a modest association between current smoking and follicular lymphoma risk and suggest that this association may not be influenced by variation in the N-acetyltransferase enzymes.
AuthorsTodd M Gibson, Karin E Smedby, Christine F Skibola, David W Hein, Susan L Slager, Silvia de Sanjosé, Claire M Vajdic, Yawei Zhang, Brian C-H Chiu, Sophia S Wang, Henrik Hjalgrim, Alexandra Nieters, Paige M Bracci, Anne Kricker, Tongzhang Zheng, Carol Kolar, James R Cerhan, Hatef Darabi, Nikolaus Becker, Lucia Conde, Theodore R Holford, Dennis D Weisenburger, Anneclaire J De Roos, Katja Butterbach, Jacques Riby, Wendy Cozen, Yolanda Benavente, Casey Palmers, Elizabeth A Holly, Joshua N Sampson, Nathaniel Rothman, Bruce K Armstrong, Lindsay M Morton
JournalCancer causes & control : CCC (Cancer Causes Control) Vol. 24 Issue 1 Pg. 125-34 (Jan 2013) ISSN: 1573-7225 [Electronic] Netherlands
PMID23160945 (Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Isoenzymes
  • Arylamine N-Acetyltransferase
  • N-acetyltransferase 1
  • NAT2 protein, human
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Arylamine N-Acetyltransferase (genetics)
  • Case-Control Studies
  • Female
  • Genetic Variation (physiology)
  • Humans
  • Isoenzymes (genetics)
  • Lymphoma, Non-Hodgkin (epidemiology, etiology, genetics)
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide (physiology)
  • Risk Factors
  • Smoking (adverse effects, epidemiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: